Saul Blecker1, Sunil K Agarwal2, Patricia P Chang3, Wayne D Rosamond4, Donald E Casey5, Anna Kucharska-Newton4, Martha J Radford6, Josef Coresh2, Stuart Katz6. 1. Department of Population Health, NYU School of Medicine, New York, New York; Department of Medicine, NYU School of Medicine, New York, New York. Electronic address: saul.blecker@nyumc.org. 2. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Department of Medicine, University of North Carolina, Chapel Hill, North Carolina. 4. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina. 5. Department of Population Health, NYU School of Medicine, New York, New York. 6. Department of Medicine, NYU School of Medicine, New York, New York.
Abstract
OBJECTIVES: The study sought to assess the quality of care for heart failure patients who are hospitalized for all causes. BACKGROUND: Performance measures for heart failure target patients with a principal diagnosis of heart failure. However, patients with heart failure are commonly hospitalized for other causes and may benefit from treatments such as angiotensin-converting enzyme (ACE) inhibitors for left ventricular (LV) systolic dysfunction. METHODS: We assessed rates of compliance with care measures for patients hospitalized with acute or chronic heart failure in the ARIC (Atherosclerosis Risk In Communities) study surveillance catchment area from 2005 to 2009. Rates of compliance were compared between patients with a principal discharge diagnosis of heart failure and those with another principal discharge diagnosis. RESULTS: Of 4,345 hospitalizations of heart failure patients, 39.6% carried a principal diagnosis of heart failure. Patients with a principal heart failure diagnosis had higher rates of LV function assessment (89.1% vs. 82.5%; adjusted prevalence ratio [aPR]: 1.07; 95% confidence interval [CI]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64.1% vs. 56.3%; aPR: 1.11; 95% CI: 1.03 to 1.20) as compared to patients hospitalized for another cause. LV assessment and ACE inhibitor/ARB use were associated with reductions in 1-year post-discharge mortality (adjusted odds ratio: 0.66, 95% CI: 0.51 to 0.85; adjusted odds ratio: 0.72, 95% CI: 0.54 to 0.96, respectively) that did not differ for patients with versus without a principal heart failure diagnosis. CONCLUSIONS: Compared with individuals hospitalized with a principal diagnosis of heart failure, heart failure patients hospitalized for other causes were less likely to receive guideline recommended care. Quality initiatives may improve care by targeting hospitalizations with either principal or secondary heart failure diagnoses.
OBJECTIVES: The study sought to assess the quality of care for heart failurepatients who are hospitalized for all causes. BACKGROUND: Performance measures for heart failure target patients with a principal diagnosis of heart failure. However, patients with heart failure are commonly hospitalized for other causes and may benefit from treatments such as angiotensin-converting enzyme (ACE) inhibitors for left ventricular (LV) systolic dysfunction. METHODS: We assessed rates of compliance with care measures for patients hospitalized with acute or chronic heart failure in the ARIC (Atherosclerosis Risk In Communities) study surveillance catchment area from 2005 to 2009. Rates of compliance were compared between patients with a principal discharge diagnosis of heart failure and those with another principal discharge diagnosis. RESULTS: Of 4,345 hospitalizations of heart failurepatients, 39.6% carried a principal diagnosis of heart failure. Patients with a principal heart failure diagnosis had higher rates of LV function assessment (89.1% vs. 82.5%; adjusted prevalence ratio [aPR]: 1.07; 95% confidence interval [CI]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64.1% vs. 56.3%; aPR: 1.11; 95% CI: 1.03 to 1.20) as compared to patients hospitalized for another cause. LV assessment and ACE inhibitor/ARB use were associated with reductions in 1-year post-discharge mortality (adjusted odds ratio: 0.66, 95% CI: 0.51 to 0.85; adjusted odds ratio: 0.72, 95% CI: 0.54 to 0.96, respectively) that did not differ for patients with versus without a principal heart failure diagnosis. CONCLUSIONS: Compared with individuals hospitalized with a principal diagnosis of heart failure, heart failurepatients hospitalized for other causes were less likely to receive guideline recommended care. Quality initiatives may improve care by targeting hospitalizations with either principal or secondary heart failure diagnoses.
Keywords:
ACCF/AHA/AMA-PCPI; ACE; ARB; American College of Cardiology Foundation, American Heart Association, and American Medical Association–Physician Consortium for Performance Improvement; CI; CMS; COPD; Centers for Medicare and Medicaid Services; LV; OR; angiotensin receptor blocker; angiotensin-converting enzyme; chronic obstructive pulmonary disease; confidence interval; eGFR; estimated glomerular filtration rate; heart failure; hospitalization; left ventricular; odds ratio; quality of care
Authors: Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Karen Pieper; Jie Lena Sun; Clyde Yancy; James B Young Journal: JAMA Date: 2007-01-03 Impact factor: 56.272
Authors: Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton Journal: Am Heart J Date: 2005-02 Impact factor: 4.749
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Christopher M O'Connor; William T Abraham; Nancy M Albert; Robert Clare; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Clyde W Yancy; James B Young; Gregg C Fonarow Journal: Am Heart J Date: 2008-10 Impact factor: 4.749
Authors: Gregg C Fonarow; Clyde W Yancy; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mandeep Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh Journal: Am Heart J Date: 2007-07 Impact factor: 4.749
Authors: Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy A Gattis; Mihai Gheorghiade; Barry Greenberg; Chris M O'Connor; Clyde W Yancy; James Young Journal: Am Heart J Date: 2004-07 Impact factor: 4.749
Authors: Sunil K Agarwal; Lisa Wruck; Miguel Quibrera; Kunihiro Matsushita; Laura R Loehr; Patricia P Chang; Wayne D Rosamond; Jacqueline Wright; Gerardo Heiss; Josef Coresh Journal: Am J Epidemiol Date: 2016-02-19 Impact factor: 4.897
Authors: Saul Blecker; Jonathan S Austrian; Leora I Horwitz; Gilad Kuperman; Donna Shelley; Meg Ferrauiola; Stuart D Katz Journal: Int J Med Inform Date: 2019-09-04 Impact factor: 4.046
Authors: Saul Blecker; Stuart D Katz; Leora I Horwitz; Gilad Kuperman; Hannah Park; Alex Gold; David Sontag Journal: JAMA Cardiol Date: 2016-12-01 Impact factor: 14.676
Authors: Jennifer Hornung Garvin; Youngjun Kim; Glenn Temple Gobbel; Michael E Matheny; Andrew Redd; Bruce E Bray; Paul Heidenreich; Dan Bolton; Julia Heavirland; Natalie Kelly; Ruth Reeves; Megha Kalsy; Mary Kane Goldstein; Stephane M Meystre Journal: JMIR Med Inform Date: 2018-01-15